专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07556824B2 Transdermal patch composition for treating vascular diseases characterized by nitric oxide insufficiency 有权
标题翻译：用于治疗以一氧化氮不足为特征的血管疾病的透皮贴片组合物
公开(公告)号：US07556824B2
公开(公告)日：2009-07-07
申请号：US10679257
申请日：2003-10-07
申请人： Joseph Loscalzo , Joseph A. Vita , Michael D. Loberg , Manuel Worcel
发明人： Joseph Loscalzo , Joseph A. Vita , Michael D. Loberg , Manuel Worcel
IPC分类号： A61F13/00 , A61K9/70 , A61L15/12 , A61L15/44
CPC分类号： A61K31/495 , A61K9/0056 , A61K9/7023 , A61K31/135 , A61K31/19 , A61K31/34 , A61K31/355 , A61K31/415 , A61K31/50 , A61K31/535 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： The present invention provides novel transdermal patch comprising a therapeutic amount of a hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds.
摘要翻译：本发明提供新颖的透皮贴剂，其包含治疗量的肼azine嗪化合物和硝酸异山梨酯和硝酸异山梨酯中的至少一种，其治疗有效剂量为上述每种化合物。

12. 发明申请

US20090118294A1 COMPOSITIONS AND METHODS RELATED TO HEART FAILURE 审中-公开
标题翻译：与心脏失效相关的组合物和方法
公开(公告)号：US20090118294A1
公开(公告)日：2009-05-07
申请号：US12270625
申请日：2008-11-13
申请人： Manuel Worcel , Michael L. Sabolinski
发明人： Manuel Worcel , Michael L. Sabolinski
IPC分类号： A61K31/50
CPC分类号： A61K31/15 , A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); reducing the number of hospital admissions for heart failure; and reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and/or the number of hospital visits); by administering to a patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), or diuretic compounds.
摘要翻译：本发明提供了减少心脏衰竭患者在单次住院期间心脏衰竭的总天数减少的方法（即减少患有心力衰竭的患者的单次住院时间）; 减少患者在医院为多次住院（即两个或多个住院期间）心力衰竭的总天数; 减少住院心脏病的人数; 降低死亡率并减少心力衰竭的住院时间（例如医院总天数和/或住院次数）; 通过向患者施用治疗有效量的（i）肼屈嗪化合物或其药学上可接受的盐，（ii）硝酸异山梨酯和/或单硝酸异山梨酯，和（iii）任选的至少一种血管紧张素转换酶抑制剂，β-肾上腺素能拮抗剂，血管紧张素II拮抗剂，醛固酮拮抗剂，心脏葡萄糖苷（洋地黄）或利尿剂。

13. 发明申请

US20060014828A1 Compositions and methods related to heart failure 审中-公开
公开(公告)号：US20060014828A1
公开(公告)日：2006-01-19
申请号：US11182886
申请日：2005-07-18
申请人： Manuel Worcel , Michael Sabolinski
发明人： Manuel Worcel , Michael Sabolinski
IPC分类号： A61K31/34 , A61K31/15
CPC分类号： A61K31/15 , A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and/or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and/or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

14. 发明申请

US20090226407A9 METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY 失效
标题翻译：治疗由氧化氮缺乏症引起的血管疾病的方法
公开(公告)号：US20090226407A9
公开(公告)日：2009-09-10
申请号：US10692724
申请日：2003-10-27
申请人： Joseph Loscalzo , Joseph Vita , Michael Loberg , Manuel Worcel
发明人： Joseph Loscalzo , Joseph Vita , Michael Loberg , Manuel Worcel
IPC分类号： A61K38/43 , A01N43/04
CPC分类号： A61K31/135 , A61K9/0056 , A61K9/7023 , A61K31/19 , A61K31/34 , A61K31/355 , A61K31/415 , A61K31/495 , A61K31/50 , A61K31/535 , A61K45/06 , A61K2300/00
摘要： The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.
摘要翻译：本发明提供治疗和/或预防以一氧化氮不足为特征的血管疾病的方法，其通过施用治疗有效量的至少一种亚硝化血管紧张素转换酶抑制剂，亚硝化β-肾上腺素能阻断剂，亚硝化胆固醇降低剂，亚硝化钙通道阻断剂，亚硝化内皮素拮抗剂，亚硝化血管紧张素II受体拮抗剂，亚硝化肾素抑制剂和任选的至少一种用于治疗心血管疾病的化合物，和/或至少一种抗氧化剂或其药学上可接受的盐，和/或至少一种可以转移的化合物或释放一氧化氮，提高内源性内源性舒张因子水平，刺激一氧化氮的内源性合成，或是一氧化氮合成酶的底物。抗氧化剂可优选为肼屈嗪化合物或其药学上可接受的盐。捐赠，转移或释放一氧化氮的化合物提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成，或者是一氧化氮合酶的底物可优选为硝酸异山梨酯和/或一硝酸异山梨酯。以一氧化氮不足为特征的血管疾病包括心血管疾病和由氧化应激引起的疾病。

15. 发明申请

US20090118293A1 METHODS FOR REDUCING HOSPITALIZATIONS RELATED TO HEART FAILURE 审中-公开
标题翻译：减少与失眠有关的医院的方法
公开(公告)号：US20090118293A1
公开(公告)日：2009-05-07
申请号：US12262762
申请日：2008-10-31
申请人： Manuel Worcel , Michael L. Sabolinski
发明人： Manuel Worcel , Michael L. Sabolinski
IPC分类号： A61K31/502 , A61P9/00
CPC分类号： A61K31/15 , A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays; (e) reducing the number of hospital admissions for heart failure; and (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and/or the number of hospital visits) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.
摘要翻译：本发明提供了（a）延长心力衰竭住院时间的方法; （b）延长首次住院心脏衰竭的时间; （c）减少患有心力衰竭的患者在医院心脏衰竭的总天数，用于单次住院（即减少患有心力衰竭的患者的单次住院时间）; （d）减少患者在医院内多次住院心衰的总天数; （e）减少住院心脏病的人数; 和（f）在有需要的患者中降低死亡率并减少心力衰竭的住院时间（例如，医院的总天数和/或住院次数），包括向患者施用治疗有效量的（i ）二氢肼屈嗪化合物或其药学上可接受的盐，（ii）硝酸异山梨酯和/或单硝酸异山梨酯，和（iii）任选的至少一种选自血管紧张素转换酶抑制剂，β-肾上腺素能拮抗剂，血管紧张素II拮抗剂，醛固酮拮抗剂，心脏葡萄糖苷（洋地黄）和利尿剂。

16. 发明申请

US20070238740A1 Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use 审中-公开
标题翻译：亚硝化和亚硝基化心血管化合物，组合物和使用方法
公开(公告)号：US20070238740A1
公开(公告)日：2007-10-11
申请号：US10568819
申请日：2004-08-20
申请人： David Garvey , L. Letts , Manuel Worcel
发明人： David Garvey , L. Letts , Manuel Worcel
IPC分类号： A61K31/41 , A61K31/4164 , A61K31/4184 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/519 , C07D233/42 , C07D233/54 , C07D239/22 , C07D257/04 , C07D401/10 , C07D403/10 , C07D471/04 , C07D487/04
CPC分类号： C07D403/10 , C07C205/40 , C07D233/68 , C07D235/18 , C07D257/04 , C07D307/52 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one cardiovascular compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and/or nitrosylated cardiovascular compounds are preferably nitrosated and/or nitrosylated aldosterone antagonists, nitrosated and/or nitrosylated angiotensin II antagonists, nitrosated and/or nitrosylated calcium channel blockers, nitrosated and/or nitrosylated endothelin antagonists, nitrosated and/or nitrosylated hydralazine compounds, nitrosated and/or nitrosylated neutral endopeptidase inhibitors and nitrosated and/or nitrosylated renin inhibitors.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的心血管化合物或其药学上可接受的盐，以及包含至少一种亚硝化和/或亚硝基化的心血管化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂的新组合物。本发明还提供了包含至少一种本发明的心血管化合物，其任选被亚硝化和/或亚硝基化的新组合物和试剂盒，以及任选的至少一种一氧化氮供体化合物和/或至少一种治疗剂。本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; （j）治疗骨质疏松症; 和（k）治疗肾病。亚硝化和/或亚硝基化的心血管化合物优选为亚硝化和/或亚硝基化的醛固酮拮抗剂，亚硝化和/或亚硝酰化的血管紧张素II拮抗剂，亚硝化和/或亚硝酰化的钙通道阻断剂，亚硝化和/或亚硝基化的内皮素拮抗剂，亚硝化和/ 化合物，亚硝化和/或亚硝基化的中性内肽酶抑制剂和亚硝化和/或亚硝基化的肾素抑制剂。

17. 发明申请

US20070191377A1 Methods for treating blood disorders with nitric oxide donor compounds 审中-公开
标题翻译：用一氧化氮供体化合物治疗血液病症的方法
公开(公告)号：US20070191377A1
公开(公告)日：2007-08-16
申请号：US10594990
申请日：2005-03-31
申请人： Manuel Worcel
发明人： Manuel Worcel
IPC分类号： A61K31/502 , A61K31/34 , A61K31/198 , A61K31/21
CPC分类号： A61K31/198 , A61K31/21 , A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
摘要： The invention describes methods for treating blood disorders or for treating the symptoms and/or complications associated with blood disorders by administering a therapeutically effective amount of at least one nitric oxide donor compound and optionally at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one therapeutic agent. The antioxidant is preferably a hydralazine compound or a pharmaceutically acceptable salt thereof. The nitric oxide donor compound is preferably N-hydroxy-L-arginine and/or isosorbide dinitrate and/or isosorbide mononitrate. The blood disorder is preferably sickle cell anemia. The complication resulting from a blood disorder is preferably pulmonary hypertension.
摘要翻译：本发明描述了通过施用治疗有效量的至少一种一氧化氮供体化合物和任选的至少一种抗氧化剂或其药学上可接受的盐来治疗血液病症或用于治疗与血液病症有关的症状和/或并发症的方法，以及 /或至少一种治疗剂。抗氧化剂优选为肼azine嗪化合物或其药学上可接受的盐。一氧化氮供体化合物优选为N-羟基-L-精氨酸和/或硝酸异山梨酯和/或一硝酸异山梨酯。血液病最好是镰状细胞性贫血。由血液病引起的并发症优选为肺动脉高压。

18. 发明申请

US20070112067A1 Nitrosated and nitrosylated prostaglandins, compositions and methods of use 失效
标题翻译：亚硝化和亚硝酰化前列腺素，组合物和使用方法
公开(公告)号：US20070112067A1
公开(公告)日：2007-05-17
申请号：US11641050
申请日：2006-12-19
申请人： David Garvey , Ricky Gaston , L. Letts , Inigo de Tejada , Sang Tam , Manuel Worcel
发明人： David Garvey , Ricky Gaston , L. Letts , Inigo de Tejada , Sang Tam , Manuel Worcel
IPC分类号： A61K31/21 , C07C203/02
CPC分类号： A61K31/5575
摘要： The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的前列腺素，以及包含至少一种亚硝化和/或亚硝基化的前列腺素的新组合物，以及任选的至少一种捐赠，转移或释放一氧化氮的化合物，提高内源性内皮水平的放松因子，刺激一氧化氮的内源性合成或是一氧化氮合酶的底物和/或至少一种血管活性剂。本发明还提供了包含至少一种前列腺素和至少一种S-亚硝基硫醇化合物和任选的至少一种血管活性剂的新型组合物。前列腺素优选为前列腺素E 1化合物，更优选前列地尔，S-亚硝基硫醇化合物优选为S-亚硝基谷胱甘肽。本发明还提供用于治疗或预防男性和女性的性功能障碍的方法，用于增强男性和女性的性反应，以及用于治疗或预防脑血管疾病，心血管疾病，良性前列腺增生（BPH），青光眼，消化性溃疡或诱导堕胎

19. 发明申请

US20070010571A1 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use 审中-公开
标题翻译：硝基化和亚硝基化心血管化合物，组合物和使用方法
公开(公告)号：US20070010571A1
公开(公告)日：2007-01-11
申请号：US10569077
申请日：2004-08-20
申请人： David Garvey , L. Letts , Manuel Worcel , Ricky Gaston
发明人： David Garvey , L. Letts , Manuel Worcel , Ricky Gaston
IPC分类号： A61K31/405 , A61K31/138 , C07D209/20
CPC分类号： C07D493/04 , C07D407/04 , C07K5/06026
摘要： The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at,least one cardiovascular compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and/or nitrosylated cardiovascular compounds are preferably nitrosated and/or nitrosylated P-adrenergic antagonists, nitrosated and/or nitrosylated angiotensinconverting enzyme (ACE) inhibitors, nitrosated and/or nitrosylated anti-hyperlipidemic compounds, and nitrosated and/or nitrosylated antithrombotic and vasodilator compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的心血管化合物或其药学上可接受的盐，以及包含至少一种亚硝化和/或亚硝基化的心血管化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂的新组合物。本发明还提供了包含至少一种本发明的心血管化合物，其任选被亚硝化和/或亚硝基化的新组合物和试剂盒，以及任选的至少一种一氧化氮供体化合物和/或至少一种治疗剂。本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; （j）治疗骨质疏松症; 和（k）治疗肾病。亚硝化和/或亚硝基化的心血管化合物优选为亚硝化和/或亚硝化的P-肾上腺素能拮抗剂，亚硝化和/或亚硝化的血管紧张素转换酶（ACE）抑制剂，亚硝化和/或亚硝化的抗高脂血症化合物，以及亚硝化和/或亚硝化的抗血栓形成和/ 血管扩张剂化合物。

20. 发明授权

US07708989B2 Methods of treating vascular diseases characterized by nitric oxide insufficiency 失效
标题翻译：治疗以一氧化氮不足为特征的血管疾病的方法
公开(公告)号：US07708989B2
公开(公告)日：2010-05-04
申请号：US10692724
申请日：2003-10-27
申请人： Joseph Loscalzo , Joseph A. Vita , Michael D. Loberg , Manuel Worcel
发明人： Joseph Loscalzo , Joseph A. Vita , Michael D. Loberg , Manuel Worcel
IPC分类号： A61K38/43 , A01N43/04
CPC分类号： A61K31/135 , A61K9/0056 , A61K9/7023 , A61K31/19 , A61K31/34 , A61K31/355 , A61K31/415 , A61K31/495 , A61K31/50 , A61K31/535 , A61K45/06 , A61K2300/00
摘要： The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.
摘要翻译：本发明提供治疗和/或预防以一氧化氮不足为特征的血管疾病的方法，其通过施用治疗有效量的至少一种亚硝化血管紧张素转换酶抑制剂，亚硝化β-肾上腺素能阻断剂，亚硝化胆固醇降低剂，亚硝化钙通道阻断剂，亚硝化内皮素拮抗剂，亚硝化血管紧张素II受体拮抗剂，亚硝化肾素抑制剂和任选的至少一种用于治疗心血管疾病的化合物，和/或至少一种抗氧化剂或其药学上可接受的盐，和/或至少一种可以转移的化合物或释放一氧化氮，提高内源性内源性舒张因子水平，刺激一氧化氮的内源性合成，或是一氧化氮合成酶的底物。抗氧化剂可优选为肼屈嗪化合物或其药学上可接受的盐。捐赠，转移或释放一氧化氮的化合物提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成，或者是一氧化氮合酶的底物可优选为硝酸异山梨酯和/或一硝酸异山梨酯。以一氧化氮不足为特征的血管疾病包括心血管疾病和由氧化应激引起的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式